Tagged with Access

Colombia Oscar Fernando Otalora Gomez, Executive Director of HB Human Bioscience, discusses the importance of bringing innovation and technology to the Colombian market, while being committed to providing medication at a reasonable price to save lives. To begin with, could you introduce HB Human Bioscience to our international audience and give…

Indonesia Evie Yulin, biopharma country director at Merck Indonesia, speaks towards the meaning of innovation in emerging countries and how the company engages in innovation beyond products. Since 2012, Merck has been implementing “Fit for 2018” – a transformation program aiming to drive the growth of the company globally. How has this…

Colombia Sandra Cifuentes, General Manager of Astellas Farma Colombia, one of the most recent entrants in the Colombian market, explains the strategic priorities for establishing a strong position in the country, where the prime focus is on bringing a collaborative approach that can unite the industry towards a more sustainable healthcare…

Ukraine Victoria Bandyk, chief operating officer of the Bioscience Group, provides insights into the unique added value and the international development of this comprehensive group of companies, which aims to support local and international companies in positioning, registering, and promoting medicines across targeted European and Asian markets, finding strategic partners across…

Austria Ana Kostova, Austrian country president for AstraZeneca, a global powerhouse in innovative drugs and R&D, discusses the opportunities and challenges of introducing innovative treatments into the Austrian healthcare system as well as AstraZeneca´s exciting pipeline, especially in the field of oncology. She also provides an insight into the future potential…

Singapore Claus Zieler discusses the Asia Pacific region’s importance to Bayer’s global operations, the company’s commitment to increasing its portfolio of innovative medicines, and the potential for innovation coming from Asian markets. Having spent four years in Japan previously, how have you had to adapt to serving the entire Asia Pacific…

Indonesia Maura Linda Sitanggang, director general at the Indonesian Ministry of Health, discusses the plans being rolled out to ensure that all Indonesians have access to medicines and how the Indonesian pharmaceutical industry has developed its self-reliance and innovativeness. How does the Ministry of Health organize its priorities and how far…

USA In 2016, rumours of a weakening FDA followed a disappointing 16 new drugs approved for the full year. However, since the beginning of 2017 the FDA has approved 26 drugs; double the amount of the mid-year average since 2007. “The eight oncology treatments approved by the FDA this year represent…

Austria Christa Wirthumer-Hoche, head of the Austrian Medicines and Medical Devices Agency (AGES) and chair of the European Medicines Agency (EMA) management board, discusses the role of AGES within Austria, similarities with other countries’ regulatory agencies, Austria’s potential as an innovation hub, and the possible relocation of the EMA to Vienna…

Colombia Kenneth Garcia, General Manager of Smith & Nephew Colombia, reveals his thoughts on the rising attractiveness of the Colombian market and the growing demand for higher standards of healthcare products with a strong willingness from the government and the private sector to improve its healthcare capabilities, while also discussing Smith…

Ukraine Natalia Zago, managing director of Takeda Ukraine, one of the leading international companies operating in the country, provides insights into her main priorities to drive the growth of the company under the conditions of significant changes in the pharmaceutical market and Ukrainian healthcare system.   Nobody can deny that Ukraine…

Indonesia Benoit Martineau, President Director at Sanofi Indonesia, explains the transformation of the Indonesian affiliate and reaffirms the strong commitment of Sanofi in helping the Indonesian government to successfully implement their patient access roadmap. Mr. Martineau, could you please introduce yourself to our international audience as well as your main areas…